1143PResponses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX). (23rd October 2018) - Hecht, J R; Naing, A; Falchook, G S; Patel, M R; Aljumaily, R; Wong, D J; Autio, K A; Wainberg, Z A; Javle, M; Bendell, J; Pant, S; Hung, A; et al.